Imagene AI

LungOI is an AI-based NSCLC multi-gene test that offers rapid biomarker profiling, facilitating informed clinical decisions.

The Lung Prediction Panel uses AI to detect eight genomic alteration biomarkers in non-small cell lung cancer (NSCLC) samples from H&E whole-slide images, delivering results in minutes.

Imagene supports the development of companion diagnostics by combining AI-based immunohistochemistry quantification, spatial analysis, and patient stratification with regulatory and deployment planning.

OI Discover uses multimodal real-world data to develop response prediction models and identify biomarker candidates from limited clinical trial cohorts.

Imagene AI integrates its Lung Prediction Panel with Mindpeak’s peakDeploy platform to expand access to image-based biomarker profiling for laboratories.

Imagene AI develops AI-powered pathology assays for precision oncology, using multimodal foundation models and real-world data to accelerate biomarker discovery and companion diagnostics.

Imagene AI and Sheba Medical Center have partnered to create a precision oncology alliance. The collaboration combines Sheba’s real-world clinical data with Imagene AI’s Cross Modality Intelligence Engine for multimodal cancer research. The alliance aims to accelerate predictive modeling and improve personalized cancer treatment translation into clinical practice.

Sep 2025newswire.comNews article

Imagene AI secures **$23 million in Series B funding**, bringing its total raised to **$45 million**. The round is led by tech billionaire **Larry Ellison**. The company develops an **adaptive AI engine** designed for precision medicine, enabling dynamic, data-driven healthcare insights.

Jul 2025newswire.comNews article

Imagene Laboratory secures accreditation from the College of American Pathologists, validating its AI-driven cancer diagnostic testing capabilities. The recognition highlights the expanding role of artificial intelligence in pathology and precision medicine. The laboratory now meets rigorous standards for diagnostic accuracy and operational excellence in oncology.

Mar 2025newswire.comNews article

Imagene integrates its AI-driven multigene panel—analyzing biopsy images to predict non-small cell lung cancer biomarkers—with Tempus AI’s real-world clinical data. The partnership aims to enhance diagnostic accuracy by merging imaging-based biomarker detection with large-scale patient datasets. Both companies specialize in oncology tools, leveraging AI to improve early cancer identification.

Feb 2025genomeweb.comNews article